Plasminogen Activator Inhibitor Type 1, Human, Recombinant (PAI 1, PAI-1)
Artikelnummer:
USB-P4256-29A1
Hersteller Artikelnummer:
P4256-29A1
Alternativnummer:
USB-P4256-29A1-2,USB-P4256-29A1-10
Hersteller:
US Biological
Kategorie:
Molekularbiologie
Plasminogen Activator Inhibitor-1 (PAI-1, Serpin E1) is a member of the serpin family of serine protease inhibitors, and is the primary inhibitor of urokinase and tissue plasminogen activator (tPA). PAI-1 is expressed predominantly in adipose, liver and vascular tissues, but is also produced by certain tumor cells. Elevated levels of PAI-1 are associated with obesity, diabetes and cardiovascular disease, and increased production of PAI-1 is induced by various obesity-related factors, such as TNFalpha, glucose, insulin, and very-low-density lipoprotein. The obesity-related elevation of PAI-1 levels, along with the consequential deficiency in plasminogen activators, can lead directly to increased risk of thrombosis and other coronary diseases. Accordingly, PAI-1 has been implicated as an important molecular link between obesity and coronary disease. PAI-1 can also specifically bind vitronectin (VTN) to form a stable active complex with an increased circulatory half-life relative to free PAI-1. Recombinant human PAI-1 is a 42.7kD protein containing 379 amino acid residues. Recombinant protein corresponding to human PAI-1, expressed in E. coli. Uniprot/Accession: P05121 Molecular Weight: ~42.7kD (379aa sequence) Biological Activity: Determined by its inhibitory effect against single chain tPA induced cleavage of a chromogenic substrate in Imidazole Buffer at 37C. Half maximal inhibition against 1ug/ml of single chain tPA was obtained at a concentration of 2ug/ml. Amino Acid Sequence: VHHPPSYVAH LASDFGVRVF QQVAQASKDR NVVFSPYGVA SVLAMLQLTT GGETQQQIQA AMGFKIDDKG MAPALRHLYK ELMGPWNKDE ISTTDAIFVQ RDLKLVQGFM PHFFRLFRST VKQVDFSEVE RARFIINDWV KTHTKGMISN LLGKGAVDQL TRLVLVNALY FNGQWKTPFP DSSTHRRLFH KSDGSTVSVP MMAQTNKFNY TEFTTPDGHY YDILELPYHG DTLSMFIAAP YEKEVPLSAL TNILSAQLIS HWKGNMTRLP RLLVLPKFSL ETEVDLRKPL ENLGMTDMFR QFQADFTSLS DQEPLHVAQA LQKVKIEVNE SGTVASSSTA VIVSARMAPE EIIMDRPFLF VVRHNPTGTV LFMGQVMEP Storage and Stability: Lyophilized and reconstituted products are stable for 6 months after receipt at -20C. Reconstitute with sterile ddH2O. Aliquot to avoid repeated freezing and thawing. Store at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
Supplied as a lyophilized powder without additives. Reconstitute with sterile dH2O to a concentration of 0.1-1mg/ml. For extended storage, the addition of 0.1% BSA or HSA is recommended. Do not vortex. Do not vortex.
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
